442 related articles for article (PubMed ID: 11053058)
1. Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Breedveld FC; Dayer JM
Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058
[TBL] [Abstract][Full Text] [Related]
2. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Herrmann ML; Schleyerbach R; Kirschbaum BJ
Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of leflunomide in rheumatoid arthritis.
Fox RI
J Rheumatol Suppl; 1998 Jul; 53():20-6. PubMed ID: 9666414
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action for leflunomide in rheumatoid arthritis.
Fox RI; Herrmann ML; Frangou CG; Wahl GM; Morris RE; Strand V; Kirschbaum BJ
Clin Immunol; 1999 Dec; 93(3):198-208. PubMed ID: 10600330
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
6. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Moon SJ; Kim EK; Jhun JY; Lee HJ; Lee WS; Park SH; Cho ML; Min JK
J Transl Med; 2017 Feb; 15(1):31. PubMed ID: 28193225
[TBL] [Abstract][Full Text] [Related]
7. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Rückemann K; Fairbanks LD; Carrey EA; Hawrylowicz CM; Richards DF; Kirschbaum B; Simmonds HA
J Biol Chem; 1998 Aug; 273(34):21682-91. PubMed ID: 9705303
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis.
Cutolo M; Sulli A; Ghiorzo P; Pizzorni C; Craviotto C; Villaggio B
Ann Rheum Dis; 2003 Apr; 62(4):297-302. PubMed ID: 12634225
[TBL] [Abstract][Full Text] [Related]
9. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation.
Xu X; Williams JW; Gong H; Finnegan A; Chong AS
Biochem Pharmacol; 1996 Aug; 52(4):527-34. PubMed ID: 8759024
[TBL] [Abstract][Full Text] [Related]
10. The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha.
Magne D; Mézin F; Palmer G; Guerne PA
Inflamm Res; 2006 Nov; 55(11):469-75. PubMed ID: 17122964
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide and malononitrilamides.
Silva Júnior HT; Morris RE
Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene S; Watanabe K; Braatz-Trulson J; Lou L
Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
[TBL] [Abstract][Full Text] [Related]
13. Suppression of experimental autoimmune neuritis by leflunomide.
Korn T; Toyka K; Hartung HP; Jung S
Brain; 2001 Sep; 124(Pt 9):1791-802. PubMed ID: 11522581
[TBL] [Abstract][Full Text] [Related]
14. Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes.
Vergne-Salle P; Léger DY; Bertin P; Trèves R; Beneytout JL; Liagre B
Cytokine; 2005 Sep; 31(5):335-48. PubMed ID: 16099671
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide: a review of its use in active rheumatoid arthritis.
Prakash A; Jarvis B
Drugs; 1999 Dec; 58(6):1137-64. PubMed ID: 10651393
[TBL] [Abstract][Full Text] [Related]
16. The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis.
Vrenken TE; Buist-Homan M; Kalsbeek AJ; Faber KN; Moshage H
J Hepatol; 2008 Nov; 49(5):799-809. PubMed ID: 18809221
[TBL] [Abstract][Full Text] [Related]
17. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.
Doscas ME; Williamson AJ; Usha L; Bogachkov Y; Rao GS; Xiao F; Wang Y; Ruby C; Kaufman H; Zhou J; Williams JW; Li Y; Xu X
Neoplasia; 2014 Oct; 16(10):824-34. PubMed ID: 25379019
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.
Li Y; Yi L; Cheng S; Wang Y; Wang J; Sun J; Zhang Q; Xu X
J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33416466
[TBL] [Abstract][Full Text] [Related]
20. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]